Prognostic Value of BRAF and KRAS Mutation in Relation to Colorectal Cancer Survival in Iranian Patients: Correlated to Microsatellite Instability

Nazemalhosseini‐Mojarad, Ehsan; Farahani, Roya Kishani; Mehrizi, Maryam; Baghaei, Kaveh; Taleghani, Mohammad Yaghoob; Golmohammadi, Mina; Peyravian, Noshad; Ashtari, Sara; Pourhoseingholi, Mohmad Amin; Aghdaei, Hamid Asadzadeh; Zali, Mohammad Reza

doi:10.1007/s12029-019-00201-4

Cited by 13 publications

(15 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, the mutation rates of BRAF was 3.96%, the BRAF mutation rate is similar to that previously reported in Iranian (5.8%, 15/258) (Nazemalhosseini-Mojarad et al, 2019), but significantly lower than the value of 16% among 1185 CRC patients from Norway (Smeby et al, 2018). On the other hand, the association between BRAF mutations and clinicopathological characteristics has not been well known in Chinese CRC patients due to the insufficient number of CRCs with BRAF mutation.…”

Section: Discussionsupporting

confidence: 87%

“…On the other hand, the association between BRAF mutations and clinicopathological characteristics has not been well known in Chinese CRC patients due to the insufficient number of CRCs with BRAF mutation. Nonetheless, reports from other countries have demonstrated that tumors with BRAF mutation are associated with tumor location, tumor grade, and mucinous production (Nazemalhosseini-Mojarad et al, 2019;Zlobec et al, 2010), our data confirmed BRAF mutations was only association with tumor differentiation. Several factors may be related to these differences, such as sample size, the distribution of age, stage, as well as racial and/or environmental differences.…”

Section: Discussionsupporting

confidence: 81%

“…Several studies had reported the frequency of BRAF mutation in CRC patients, but the number of samples was limited in most of studies. The mutation rate was 5-20% in western countries (Nazemalhosseini-Mojarad et al, 2019;Smeby et al, 2018). But in Chinese, only 5% CRC patients harbored BRAF mutation (Shen et al, 2011;Ye et al, 2015;Yunxia et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China

Zhang

Wang

et al. 2020

PeerJ

View full text Add to dashboard Cite

Objective To investigate the frequency and prognostic role of the human epidermal growth factor receptor 2 gene (HER2) and BRAF V600E gene mutation in Chinese patients with colorectal cancer (CRC). Methods Clinicopathological and survival information from 480 patients with stage I–III CRC were reviewed and recorded. HER2 amplification was analyzed by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), BRAF V600E mutation was tested by IHC and Sanger sequencing. The relationship between HER2 and BRAF V600E mutation status and clinicopathological characteristics and outcomes were determined. Results The amplification of HER2 and BRAF V600E mutation were identified in 27 of 480 (5.63%) and 19 of 480 (3.96%) CRC patients, respectively. HER2 amplification significantly correlated with greater bowel wall invasion (P = 0.041) and more advanced TNM stage (I vs. II vs. III; 0 vs 5.78% vs. 7.41%, P = 0.013). Patients suffering from tumors with poor differentiation had a higher incidence rate of BRAF V600E mutation than those with moderate/well differentiation (7.77% vs 2.92%, P = 0.04). HER2 amplification was an independent prognostic factor for worse disease-free survival (DFS) (HR = 2.53, 95% CI: 1.21–5.30, P = 0.014). Conclusion The prevalence of HER2 amplification and BRAF V600E mutation in stage I–III CRC patients in Chinese was 6% and 4%, respectively, and HER2 amplification appeared to be associated with a worse DFS. More comprehensive molecular classification and survival analysis are needed to validate our findings.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Discussionsupporting

confidence: 81%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China

Zhang

Wang

et al. 2020

PeerJ

View full text Add to dashboard Cite

show abstract

“…Colorectal cancer (CRC) is identified as one of the leading causes of morbidity and mortality around the world. It is known as the third most prevalent cancer in Iran and its mortality rate has been growing in recent years [ 1 – 3 ]. In the 1996–2000 period, the incidence rate of CRC was 7–8 per 100,000 for both males and females in Iran [ 4 ], while this rate increased to 11.8 and 16.5 (per 100,000) for females and males, respectively, in 2014 [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Association between colorectal cancer and Fusobacterium nucleatum and Bacteroides fragilis bacteria in Iranian patients: a preliminary study

Shariati

Razavi

Ghaznavi‐Rad

et al. 2021

Infect Agents Cancer

View full text Add to dashboard Cite

Background and aim Recent studies have proposed that commensal bacteria might be involved in the development and progression of gastrointestinal disorders such as colorectal cancer (CRC). Therefore, in this study, the relative abundance of Fusobacterium nucleatum, Bacteroides fragilis, Streptococcus bovis/gallolyticus, and Enteropathogenic Escherichia coli (EPEC) in CRC tissues, and their association with clinicopathologic characteristics of CRC was investigated in Iranian patients. Moreover, the role of these bacteria in the CRC-associated mutations including PIK3CA, KRAS, and BRAF was studied. Method To these ends, the noted bacteria were quantified in paired tumors and normal tissue specimens of 30 CRC patients, by TaqMan quantitative Real-Time Polymerase Chain Reaction (qPCR). Next, possible correlations between clinicopathologic factors and mutations in PIK3CA, KRAS, and BRAF genes were analyzed. Results In studied samples, B. fragilis was the most abundant bacteria that was detected in 66 and 60% of paired tumor and normal samples, respectively. Furthermore, 15% of the B. fragilis-positive patients were infected with Enterotoxigenic B. fragilis (ETBF) in both adenocarcinoma and matched adjacent normal samples. F. nucleatum was also identified in 23% of tumors and 13% of adjacent normal tissue samples. Moreover, the relative abundance of these bacteria determined by 2-ΔCT was significantly higher in CRC samples than in adjacent normal mucosa (p < 0.05). On the other hand, our findings indicated that S. gallolyticus and EPEC, compared to adjacent normal mucosa, were not prevalent in CRC tissues. Finally, our results revealed a correlation between F. nucleatum-positive patients and the KRAS mutation (p = 0.02), while analyses did not show any association between bacteria and mutation in PIK3CA and BRAF genes. Conclusion The present study is the first report on the analysis of different bacteria in CRC tissue samples of Iranian patients. Our findings revealed that F. nucleatum and B. fragilis might be linked to CRC. However, any link between gut microbiome dysbiosis and CRC remains unknown.

show abstract

“…MSI occurs in CRC patients by two different mechanisms. In sporadic cases, hypermethylation of the MLH1 promoter and sometimes sporadic mutations are the main causes, while in hereditary nonpolyposis colorectal cancer the main cause is a germline mutation in the MMR genes (Nazemalhosseini Mojarad et al, 2016). Determination of MSI is important in prognosis, prediction, therapeutic implications and classification of CRC (Sinicrope and Sargent, 2012;Alwers et al, 2019;Hu et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

Can <i>hypoxia-inducible factor-1α</i> overexpression discriminate human colorectal cancers with different microsatellite instability?

et al. 2021

Self Cite

View full text Add to dashboard Cite

Prognostic Value of BRAF and KRAS Mutation in Relation to Colorectal Cancer Survival in Iranian Patients: Correlated to Microsatellite Instability

Cited by 13 publications

References 36 publications

HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China

HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China

Association between colorectal cancer and Fusobacterium nucleatum and Bacteroides fragilis bacteria in Iranian patients: a preliminary study

Can <i>hypoxia-inducible factor-1α</i> overexpression discriminate human colorectal cancers with different microsatellite instability?

Contact Info

Product

Resources

About